Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...
From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report ...
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...
Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data ...
The Motley Fool on MSN4d
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?Eli Lilly lost the momentum it had during the first half of the ... Let's consider just three: First, the company's ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out. Image source: Getty Images.
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...
Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the company’s marketing, shifting its focus to the Lilly brand, its patients and an ...
Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback